Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

Documenti analoghi

• A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
  di: Goswami, Trishna, et al.
  Pubblicazione: (2014)
• Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
  di: Schiopu, Elena, et al.
  Pubblicazione: (2016)
• Rituximab in Chronic Lymphocytic Leukemia
  di: James, Danelle F., et al.
  Pubblicazione: (2011)
• Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
  di: Goldberg, Avram, et al.
  Pubblicazione: (2014)
• Single Dose of Glycoengineered Anti-CD19 Antibody (MEDI551) Disrupts Experimental Autoimmune Encephalomyelitis by Inhibiting Pathogenic Adaptive Immune Responses in the Bone Marrow and Spinal Cord while Preserving Peripheral Regulatory Mechanisms()
  di: Chen, Ding, et al.
  Pubblicazione: (2014)